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Circulating tumor cells (CTCs) are tumor cells found in the peripheral blood that putatively
originate from established sites of malignancy and likely have metastatic potential.
Analysis of CTCs has demonstrated promise as a prognostic marker as well as a source
of identifying potential targets for novel therapeutics. Isolation and characterization of
these cells for study, however, remain challenging owing to their rarity in comparison
with other cellular components of the peripheral blood. Several techniques that exploit the
unique biochemical properties of CTCs have been developed to facilitate their isolation.
Positive selection of CTCs has been achieved using microfluidic surfaces coated with
antibodies against epithelial cell markers or tumor-specific antigens such as EpCAM
or prostate-specific membrane antigen (PSMA). Following isolation, characterization of
CTCs may help guide clinical decision making. For instance, molecular and genetic
characterization may shed light on the development of chemotherapy resistance and
mechanisms of metastasis without the need for a tissue biopsy. This paper will review
novel isolation techniques to capture CTCs from patients with advanced prostate cancer,
as well as efforts to characterize the CTCs. We will also review how these analyzes can
assist in clinical decision making. Conclusion: The study of CTCs provides insight into the
molecular biology of tumors of prostate origin that will eventually guide the development
of tailored therapeutics. These advances are predicated on high yield and accurate isolation
techniques that exploit the unique biochemical features of these cells.
Keywords: prostate cancer, circulating tumor cells (CTCs), prostate-specific membrane antigen (PSMA),
microfluidic device, androgen receptor (AR)
INTRODUCTION
Tumormetastases are amajor cause of cancermorbidity andmor-
tality. The precise mechanisms underlying the development of
metastases, however, remain poorly understood. Simply stated,
this process requires the migration of malignant cells from a pri-
mary tumor to distant sites where these cells establish secondary
tumors. Circulating tumor cells (CTCs), which were first detected
in the blood of an autopsy patient who died from cancer in 1869,
are thought to represent tumor cells in transit, some of which
will result in metastases (Ashworth, 1869). These cells are capable
of intravasation from a primary tumor, undergoing phenotypic
alterations that enable intravascular survival, extravasation from
the blood vessel, implantation in a target tissue, and proliferation
to form a tumor metastasis. Attempts to study CTCs are lim-
ited by their rarity, with concentrations as low as one CTC per
billion circulating hematopoietic cells. CTCs must therefore be
enriched, isolated, and properly identified, in order to be clinically
useful. Techniques that exploit the unique physical and biochem-
ical features of CTCs are currently being developed and utilized
in order to isolate and identify CTCs from whole blood sam-
ples obtained from cancer patients. Currently, there are numerous
techniques available to detect and isolate CTCs (Table 1). With
the exception of the CellSearch Circulating Tumor Cell Test, these
techniques have not yet been approved by the Food and Drug
Administration (FDA) for clinical use. CTC enumeration using
the CellSearch device has already been shown to correlate with
patient outcomes in a variety of malignancies, including prostate
cancer (Danila et al., 2007). Capture technologies may also pro-
vide rare opportunities to performmolecular and genetic analyses
of tumor-derived cells at sequential time points without invasive
tissue biopsies. Thus, CTCs conceptually provide insight into the
biology of a patient’s tumor that may facilitate the development
of new therapeutic options and enable clinicians to tailor therapy
to an individual patient in a longitudinal fashion (van de Stolpe
et al., 2011). It follows that CTC isolation can replace biopsies
and noninvasively yield valuable information about the evolving
status of a patient’s disease.
Analyzing peripheral blood is an attractive alternative to cur-
rently available methods of obtaining tissue in prostate can-
cer owing to the unique challenges presented by this disease.
A man with prostate cancer may not develop metastases until
many years (5–15 years) after treatment of his original tumor in
the prostate. Thus, performing a molecular analysis of archived
prostate cancer tissue may be complicated by the inability to
obtain old pathology specimens and by the possible irrelevance
of that tissue sample to the current status of the patient’s disease.
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Table 1 | Summary of techniques used to isolate prostatic CTCs.
Method Mechanism Volume of Capture References
blood used (ml) rate
Density gradient centrifugation Differential migration of CTCs
during centrifugation
Variable 70% Rosenberg et al., 2002;
Gertler et al., 2003; Kuhn
and Bethel, 2012
Size-dependent selection Separation based on cell diameter 6–7.5 90% Vona et al., 2000; Lin et al.,
2010; Farace et al., 2011
Immunomagnetic bead-based
capture (CellSearch)
Positive selection using EpCAM
coated magnetic beads
7.5 85% Tibbe et al., 2002; Allard
et al., 2004; Balic et al., 2005
Antibody-based negative selection Depletion of normal blood cells
using CD-45 coated magnetic
beads
2.5ml 52–88.4% Wang et al., 2000; Zigeuner
et al., 2000, 2003; Jatana
et al., 2010; Liu et al., 2011;
Schmidt et al., 2004
Flow cytometry Cell sorting using fluorescently
labeled epithelial antigens
NA NA Racila et al., 1998; He et al.,
2008; Wu et al., 2011
Microfluidic device Positive selection of CTCs using
antibodies attached to microfluidic
device
1–5.1 60–91.8% Nagrath et al., 2007;
Gleghorn et al., 2010; Stott
et al., 2010a,b; Mayer et al.,
2011; Kirby et al., 2012;
Santana et al., 2012
Ideally, a tumor biopsy for molecular study would be obtained
at the time of relapse, but as many men have only bone metas-
tases, it is difficult to obtain adequate and representative tumor
cells for study. In a disease for which a blood test measuring
prostate specific antigen (PSA) is sufficiently specific to support
the diagnosis of prostate cancer, it is difficult clinically to justify
a biopsy. Consequently, analysis of peripheral blood overcomes
these obstacles by easily providing clinically relevant tumor cells
for study.
Ideally, a robust CTC capture technique would be highly sen-
sitive, specific, reproducible, and automated (Doyen et al., 2012).
It should have the ability to reliably capture a high percentage of
CTCs present in a sample while minimizing the number of false
positive events and contamination from non-malignant cells. The
design of the test should be simple enough that it can be mass-
produced and be performed in clinical laboratories with minimal
inter-operator variability. It should also have the ability to both
quantify and characterize CTCs in order to limit operator bias.
Most importantly, in order to be clinically useful, a CTC capture
technology should have proven clinical relevance confirmed in
multiple prospective clinical trials. In this chapter, we will review
the currently available CTC enrichment technologies with an
emphasis on prostate cancer as well highlight current and future
applications of these technologies.
CTC DETECTIONMETHODS
Accurate characterization of CTCs is essential to the develop-
ment of these cells as a clinical biomarker and substrate for
laboratory experimentation. There is currently, however, no “gold
standard” approach for the specific identification of CTCs. This is
essential, in part, because most available CTC enrichment tech-
nologies yield samples composed of hematopoietic cells, CTCs,
and, in some cases, benign epithelial cells. Genomic analysis
and surface antigen detection are the two most commonly used
methods for CTC detection. Reverse transcription polymerase
chain reaction (RT-PCR) and Fluorescence in situ hybridiza-
tion (FISH) have been used to identify tumor-specific genetic
and chromosomal features in order to differentiate CTCs from
contaminating cells. Immunofluorescent microscopy is utilized
to detect epithelial specific antigens such as epithelial cell
adhesion molecule (EpCAM) or cytokeratin (CK), or prostatic
antigens such as PSA and prostate-specific membrane antigen
(PSMA).
POLYMERASE CHAIN REACTION
Reverse transcription-PCR is highly sensitive for identifying the
presence of CTCs and is able to detect a single malignant cell
among ten million peripheral blood mononuclear cells (PBMCs)
(Gomella et al., 1997). In addition to its sensitivity, RT-PCR
has the potential to detect mRNA from CTC fragments that
may otherwise not be detected through direct visualization by
immunohistochemistry (Sun et al., 2011). This technology has
been used in various ways to detect CTCs. In early experiments,
CTC capture was performed on whole blood samples to detect
tumor-specific genes. Extracellular RNA is highly unstable and its
presence in peripheral blood suggests the existence of circulating
cells expressing tumor-specific transcripts (Seiden et al., 1994).
For instance, detection of circulating prostate-specific RNA tran-
scripts for PSA or PSMA is thought to indicate the presence of
prostatic CTCs. The first study to detect CTCs from venous blood
samples using RT-PCR was performed in 1992 by Moreno et al.
(1992). They identified PSA mRNA in blood samples from 4 of
12 patients with metastatic prostate cancer and in none of the
17 controls, including subjects with benign prostatic hypertrophy
(Moreno et al., 1992). Subsequent studies of PCR in prostate can-
cer have utilized PSMA, kallikrein-2 (hK2), and PTI-1, in addition
to PSA, as prostate-specific markers (Olsson et al., 1997; Kurek
et al., 2004).
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There are several potential limitations to RT-PCR. It suffers
from poor specificity, as it may detect target RNA shed by nor-
mal prostatic cells. Furthermore, “illegitimate transcripts,” tissue-
specific genes that are expressed such as spliced transcripts in
non-specific tissues, may also lead to false positive results (Chelly
et al., 1989; Zippelius and Pantel, 2000). For example, in a quality-
control study, PSA and PSMA were detected in non-prostatic
negative control cell lines and healthy donor blood, which upon
further analysis were found to be perfectly homologous with the
exception of specific sequence deletions or point mutations not
found in RNA transcripts native to prostatic tissue (Gala et al.,
1998).
This issue has been addressed in part by the introduction
of quantitative PCR (Q-PCR), which increases the specificity of
mRNA detection by use of transcript-specific probes and enables
the determination of mRNA copy number such that above a spe-
cific threshold a transcript is thought to be of malignant origin
(Pantel et al., 2008). In one study, PSA mRNA copy number
used as a surrogate for CTC count was predictive of recurrence
after radical prostatectomy (Yates et al., 2012). Several studies
have shown significant differences in PSA and PSMAmRNA copy
number among patients with benign prostatic hypertrophy, local-
ized prostate cancer, and metastatic disease (Zhang et al., 2008;
Kalfazade et al., 2009). A study using Q-PCR for Kallikrein-2 (klk-
2), PSA, and prostate specific stem cell antigen (PSCA) mRNA,
copy number was concordant with CellSearch Circulating Tumor
Cell Test CTC counts, and were predictive of metastatic disease vs.
localized prostate cancer. It should be noted that there was 95%
concordance for patients withmore than 15 CTCs but diminished
significantly for CTC counts less than 5 cells per 7.5ml of blood
(Helo et al., 2009).
Nevertheless, the PCR approach has many potential draw-
backs. Expression of target RNA markers varies significantly
between patients and among different tumor cells derived from
the same patient, complicating the interpretation of absolute
RNA copy number. Additionally, false negative results may occur
because of low levels of target RNA expression in patients who
have CTCs and metastatic disease. Furthermore, this technique
is not able to distinguish between viable and non-viable CTCs.
Finally, PCR does not allow for the direct visualization of CTCs
and further molecular analysis using other laboratory techniques
(Sun et al., 2011).
SURFACE MARKER DETECTION
Immunofluorescent staining is one of the most widely used
methods of identifying CTCs enriched from heterogeneous cell
populations (Figure 1). This allows for direct visualization of cells
by fluorescent microscopy and for discrimination of CTCs from
surrounding leukocytes by differential antigen expression. Nuclei
are identified using DAPI, a fluorescent molecule that binds to the
adenine- and thymine-rich regions of DNA (Zink et al., 2003).
Anti-EpCAM and anti-CK antibodies are then used to confirm
the cells are of epithelial origin. Leukocytes are differentiated from
epithelial cells by the presence of CD45, a tyrosine phosphatase
that is expressed on hematopoietic cells. Using common plat-
forms such as CellSearch, a cell is said to be a CTC if it is DAPI
positive, stains positively for CK or EpCAM, and stains negatively
for CD45 (Allard et al., 2004). Interestingly, cell populations co-
expressing epithelial markers and CD45 have been detected using
CellSearch and other CTC isolation technologies. The significance
of these cells is poorly understood and these cells are currently
excluded from enumeration (Yu et al., 2011).
Antibodies directed against PSA and PSMA provide additional
specificity to immunofluorescent identification of prostatic CTCs
(Wang et al., 2000; Stott et al., 2010b). As mentioned previously,
PSMA is a non-secreted protein expressed in prostatic tissues
and to a much lesser extent, non-prostatic cell types such as
renal tubular cells and intestinal epithelial cells (Troyer et al.,
1995; Bostwick et al., 1998; Sweat et al., 1998; Sokoloff et al.,
2000). Its expression is significantly upregulated on prostate can-
cer cells and is also seen in the neovasculature of the majority of
solid-organ malignancies. PSA is a kallikrein found in high con-
centrations in prostatic cells and seminal tissues, and to a lesser
degree in non-prostatic tissue types such as mammary, lung, and
uterine tissue (Wei et al., 1997; Fortier et al., 1999; Mannello
and Gazzanelli, 2001). Other fluorescently labeled antibodies may
also be employed to detect subcellular localization of proteins of
interest. For example, antibodies that recognize androgen recep-
tor (AR) and tubulin have been used in prostate cancer CTCs
to determine changes in the distribution of these proteins in
the presence of androgens before and after taxane treatment to
determine susceptibility to these agents (Darshan et al., 2011).
Several different prostatic CTC morphologies have been iden-
tified using immunofluorescent microscopy. Large cells with
irregularly shaped nuclei are the predominant CTC cell type.
Other cell morphologies include very large fragile cells with
loose chromatin, CK- and PSMA-positive enucleated cells, cel-
lular debris, stem cell-like cells, and micro-clusters composed of
3–100CTCs. The significance of these different morphologies is
uncertain but may represent two distinct populations of cells;
one which has no reproductive ability, and the other with growth
potential and consequently metastatic potential (Wang et al.,
2000). Of note, although the biological significance of CTC frag-
ments is unknown, there is also evidence that enucleated CTCs
and CTC fragments correlate with patient outcomes in prostate
cancer (Coumans et al., 2010).
In addition to immunofluorescence, flow cytometry has been
frequently used to detect prostatic CTCs on the basis of surface
antigen expression (Racila et al., 1998;Heet al., 2008). Inone study,
a fluorescently labeled phosphoramidate peptidomimetic PSMA
inhibitorwasusedtodetectPSMApositivecellswithflowcytometry
(Wu et al., 2011). The authors found that there was reasonable
concordance between the number of cells spiked in a sample
and the number determined by flow cytometry (Wu et al., 2011).
Prostate cancer CTCs isolated by flow cytometry cell sorting can
also be analyzed by multiplex RT-PCR for expression prostate-
specific mRNAs such as PSA, AR, and the prostate cancer specific
gene fusion TMPRSS2 (Danila et al., 2011).
FLUORESCENCE in situ HYBRIDIZATION
Visual detection of tumor-specific genomic material is an
alternate means of detecting and characterizing CTCs after
enrichment with the added benefit of providing potentially clin-
ically useful information. FISH is technique that uses fluorescent
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FIGURE 1 | Immunofluorescent staining of prostate cancer CTC. CTC isolated from patient with CRPC using negative selection. (A) DAPI; (B) PSMA; (C)
Cytokeratin; (D) CD-45; (E) Composite image.
nucleic acid based probes that hybridize with genes of interest
that are visualized using fluorescent microscopy. Several stud-
ies have successfully employed FISH to detect prostatic CTCs
from enriched blood samples. In one study, enumerator probes
designed to detect chromosomal aneusomy typical of prostatic
malignancies identified prostatic CTCs in samples enriched using
anti-EpCAM coated immunomagnetic beads. Interestingly, the
authors found concordance between the chromosomal abnormal-
ities detected in CTCs with those found in the primary tumor in
a significant proportion of cases, supporting the theory that these
cells are indeed tumor derived (Fehm et al., 2002). FISH probes
have been used to detect AR amplification, gain of the MYC onco-
gene, and loss of the 8p gene locus in CTCs enriched using the
CellSearch Circulating Tumor Cell Test. FISH using these probes
also demonstrated that prostatic CTCs have similar cytogenetic
profiles to advanced prostatic tumors, a finding that is consis-
tent with data correlating higher CTC counts with poor clinical
outcomes (Leversha et al., 2009).
CTC ENRICHMENT METHODS
DENSITY-DEPENDENT ENRICHMENT
Density-gradient centrifugation separates CTCs from whole
blood based on the differential migration of cells through a fluid
in a density-dependent manner during centrifugation. Whole
blood centrifuged using a density gradient solution such as ficoll-
paque™ separates blood into a layer of plasma, PBMCs, and
an anucleate cell layer composed of erythrocytes and platelets.
As mononuclear cells, CTCs migrate to the PBMC layer, which
may be isolated for further processing. The advantages of this
technique are that it is relatively inexpensive, easy to perform,
and yields intact CTCs that can be subjected to further experi-
mentation. Perhaps most importantly, it enables the capture of
CTCs without relying on the expression of epithelial-specific sur-
face markers commonly used in positive selection techniques
(Sun et al., 2011). Under optimal conditions, density gradient
centrifugation is able to capture ∼70% of CTCs present in a
sample. The remaining cells are likely lost in the plasma or anu-
cleate cell layer. The negative aspect of this approach is that
samples obtained through this method are impure and are over-
whelmingly composed of hematopoietic mononuclear cells. This
makes the detection of CTCs using immunohistochemistry both
difficult and time consuming. A newer density gradient solu-
tion, Oncoquick™, which employs a porous membrane, has been
shown to prevent cross-contamination between layers and to
improve sample purity (Rosenberg et al., 2002; Gertler et al.,
2003). Nevertheless, because samples processed in this man-
ner have significant leukocyte contamination, density gradient
centrifugation is most often used as a precursor to other CTC
enrichment procedures such as PCR-based and negative selection
techniques.
A variation of density-gradient centrifugation is to use high-
density imaging following isolation and immunostaining to iden-
tify CTCs using multiple fluorescent channels to produce high
quality and high resolution digital images that retain fine cyto-
logic details of nuclear contour and cytoplasmic distribution
(Marrinucci et al., 2012). This enrichment-free strategy results in
high sensitivity and high specificity, but still lacks the ability for
further molecular analysis of identified CTCs.
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SIZE-DEPENDENT SELECTION
In general, CTCs that emanate from solid tumors have a larger
diameter and volume than other hematological cells found in
the circulation. Consequently, many investigators have tried to
exploit this characteristic in designing approaches to capture
CTCs. The most common approach is to use a filtration-based
device in which whole blood is passed through a filter with an
8µm pore diameter, enabling the passage of most hematopoi-
etic cells while retaining larger cells such as CTCs. Isolated cells
are then stained for epithelial surface markers in order to iden-
tify the CTC population. This method, entitled ISET, has a high
capture efficiency for cells >8µm in diameter, which ranges
between 86% and 100% of CTCs. It is sensitive enough to iso-
late a single micro-pipetted tumor cell added to one milliliter
of blood and yields CTCs that are amenable to further experi-
mentation such as PCR and flow cytometry (Vona et al., 2000;
Zabaglo et al., 2003; Lin et al., 2010). In one study, a portable
filter-based device achieved 90% capture efficiency from blood
spiked with a prostate cancer cell line and found that it enriched
more prostatic CTCs from more patient samples than did the
FDA-approved CellSearch device (Lin et al., 2010). A prospec-
tive trial of 60 patients, 20 of whom had PC, further established
ISET’s sensitivity for detecting prostatic CTCs when compared
with CellSearch (Farace et al., 2011). This approach has several
practical advantages; it is relatively inexpensive and easy to per-
form (Lin et al., 2010). Furthermore, it does not rely on surface
marker expression, which may vary widely, leading to inefficient
cell capture. Filtration-based devices, however, may lack sensi-
tivity when used to isolate CTCs from patient blood samples.
Cell lines used to assess sensitivity and specificity of these devices
tend to be composed of homogeneous, large tumor cells that may
be consistently captured using this system. Patient-derived CTCs
are heterogeneous and may not be large enough to be enriched.
Thus, size-dependent filtration may underestimate the true num-
ber of CTCs in a given patient’s blood (Wang et al., 2000; Stott
et al., 2010b). Pore size may also limit the specificity of ISET-
based devices, as certain classes of hematopoietic cells, such as
neutrophils, plasma cells, and macrophages, are larger than 8µm
in diameter. Additionally, althoughmost lymphocytes are 7–8µm
in diameter, larger lymphocytes may be captured, further limiting
the specificity of this technology.
NEGATIVE SELECTION BY USE OF IMMUNOMAGNETIC BEADS
CTCs isolated from the mononuclear cell layer generated by
density gradient centrifugation can be further purified using fer-
romagnetic anti-CD45 coated beads (Zigeuner et al., 2003). CD45
is a protein tyrosine phosphatase that is present on all hematopoi-
etic cells with the exception of plasma cells and erythrocytes and
is typically not expressed in epithelial cells (Stelzer et al., 1993).
CTCs are negatively selected by depleting CD45-positive cells
from a blood sample. Cells that bind to the beads are separated
from the sample using a magnetic field. This technique has a
reported capture efficiency ranging from 52% to 88%, but still has
many of the limitations of density gradient centrifugation. The
probability of isolating one cell spiked into one million leukocytes
is 93.3% (Wang et al., 2000; Zigeuner et al., 2000). This technique
has been used to detect cells in a variety of malignancies including
prostate cancer (Wang et al., 2000; Schmidt et al., 2004; Yang et al.,
2009). In one study, negative selection was used to isolate CTCs
in patients with metastatic prostate cancer with a PSA decline
while undergoing cytotoxic chemotherapy, demonstrating that
CTCs may be present despite evidence of biochemical response
to chemotherapy (Schmidt et al., 2004). A major advantage of
this technique is that it does not rely on the expression of tumor-
specific markers, enabling capture of cells that would otherwise be
missed by positive selection methods (Liu et al., 2011). Negative
selection also yields intact CTCs that are amenable to further
experimentation. Samples isolated using this technique, however,
still suffer from a lack of purity because not all CD45-positive
cells are removed during sample processing. Because this process
requires density gradient centrifugation, it also lacks sensitivity
owing to the loss of cells in plasma or RBC layers. Additionally,
negative selection by use of CD45-coated beads also adds sev-
eral washing steps that may further contribute to low capture
efficiencies.
POSITIVE SELECTION BY USE OF IMMUNOMAGNETIC BEADS
Ferromagnetic beads are also used to positively select for prostate
cancer CTCs by exploiting their expression of epithelial cell-
surface antigens. Cells isolated during density gradient cen-
trifugation are incubated with anti-EpCAM and anti-CK coated
magnetic beads, which bind to CTCs and remove them from
the sample when a magnet is applied (Brandt et al., 1996; Jost
et al., 2010). EpCAM is a type I membrane protein that functions
as a cell adhesion molecule in epithelial and adenomatous cell
types and is highly overexpressed in various carcinomas includ-
ing prostate cancer (Litvinov et al., 1996; Mukherjee et al., 2009).
CK is an intermediate filament component of the cytoplasm of
epithelial cells and, to a lesser degree, in non-epithelial cell types
including smooth muscle and endothelial cells (Franke et al.,
1979; Mattey et al., 1993). In 2000, Wang et al. described isolation
of CTCs from peripheral blood with centrifugation density gradi-
ents and magnetic cell sorting (Wang et al., 2000). This technol-
ogy has evolved and today capture devices utilizing this approach
are one of the most extensively studied methods of enriching
CTCs. The CellSearch Circulating Tumor Cell Test device, which
is the only FDA-approved test for CTC enrichment, positively
selects CTCs from 7.5ml of whole blood using EpCAM coated
magnetic beads, separates them from other blood components
using amagnetic field, and immunofluorescently labels themwith
4′,6-diamidino-2-phenylindole (DAPI), anti-CD45 and anti-CK
antibodies. A computer screen displays presents an operator with
images of cells for review and enumeration (Tibbe et al., 2002).
This method is 85% sensitive for the detection of cultured breast
cancer cells spiked into whole blood (Riethdorf et al., 2007). This
device has been shown to have a low false-positive rate in a series
of 2,183 patients with metastatic cancers; CTCs were detected
in 36% of patient samples and 0.3% of healthy controls (Allard
et al., 2004). In the subset of patients with metastatic prostate
cancer, more than two CTCs were detected in 37% of patients
(Allard et al., 2004). It has also been shown to be more sen-
sitive and specific than density-dependent centrifugation with
Oncoquick™ (Balic et al., 2005). Cells captured from patients
withmetastatic prostate cancer by use of this device have also been
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shown to possess other molecular features of prostate cancer cells
such as AR gene amplification (Shaffer et al., 2007; Attard et al.,
2009).
Despite multiple studies validating the CellSearch system’s
prognostic value as related to CTC enumeration, several impor-
tant caveats limit its usefulness. It is both expensive and time
consuming to perform. The CellSearch device fixes cells prior
to staining them, significantly limiting the ability to perform
subsequent functional assays and nucleic acid analysis (Stott
et al., 2010b). Most importantly, the sensitivity of this device
is limited by its use of EpCAM-based detection (Lara et al.,
2004). CTCs express variable levels of EpCAM in vivo, due, in
part, to downregulation of epithelial surface markers. This pro-
cess, known as epithelial-to-mesenchymal transition (EMT), is
a process in which epithelial CTCs assume a mesenchymal phe-
notype in preparation for extravasation and implantation in
metastatic sites (He et al., 2010; Armstrong et al., 2011). These
cells are more likely to metastasize and have been linked to
more aggressive prostate cancers in a number of clinical stud-
ies (Tomita et al., 2000; Gravdal et al., 2007). Evidence for EMT
has been found in CTCs that express both epithelial markers
such as CK and EpCAM and mesenchymal markers such as
vimentin, e-cadherin, and CD133 (Armstrong et al., 2011). The
co-expression of these markers is thought to represent an inter-
mediate state between the two cell types (Armstrong et al., 2011).
CTCs that undergo EMT are less likely to express high levels of
EpCAM and may therefore evade capture by anti-EpCAM anti-
bodies (Santana et al., 2012). The superior capture efficiency
of non-EpCAM based capture technologies such as ISET and
PSMA microfluidic devices may, in part, be explained by this
phenomenon.
MICROFLUIDIC DEVICES
Microfluidic devices have demonstrated high capability to enrich
CTCs from whole blood. One example, the “CTC-chip” is com-
posed of an array of antibody-coated microscopic posts arranged
as equilateral triangles through which a blood sample is flowed.
As described, the arrangement of the posts is designed to min-
imize the shear forces that cells are exposed to while within the
device. CTCs within the sample collide with the posts and are
specifically captured by the antibodies used to coat them (Nagrath
et al., 2007). In 2007, Nagrath et al. successfully employed a CTC-
chip functionalized with anti-EpCAM antibodies to isolate CTCs
from whole blood taken from patients with a range of epithe-
lial malignancies. Capture efficiency of approximately 60% was
determined by spiking blood from healthy donors with a non-
small cell lung cancer cell line. Interestingly, capture efficiency
was not diminished by using cell lines with low levels of EpCAM
expression. The authors were able to identify CTCs in 115 of 116
(99%) samples taken from patients with breast, colon, pancre-
atic, or prostate cancer with an average purity of 49–67%. Similar
to the CellSearch Circulating Tumor Cell Test device, in a lim-
ited analysis, the authors were able to correlate patient outcomes
and response to treatment with the number of CTCs captured
(Nagrath et al., 2007).
The same investigators developed what they term a “her-
ringbone chip” to use the vortical flow induced by anisotropic
surface grooves to generate a device exhibiting chaotic advec-
tion (Stroock et al., 2002). The device consists of eight micro-
channels etched with periodically occurring herringbone-shaped
grooves and functionalized with anti-EpCAM monoclonal anti-
bodies. The herringbone device has a capture efficiency of
91.8% +/−5.2% in cell spiking experiments using PC-3 cells,
and CTCs were detected in 93% of samples from patients
with metastatic prostate cancer. The design of the herringbone
device chip enabled cell capture at 50% more efficiency than
the post-based anti-EpCAM device from the same investigators.
Captured cells are again amenable to further experimentation
such as PCR and on-chip immunofluorescent staining (Stott
et al., 2010a).
Despite showing effective capture using cell lines with low
levels of EpCAM expression, it is unclear whether chips function-
alized with anti-EpCAM antibodies can efficiently capture cells
that have undergone EMT in patient samples. CTCs may express
lower levels of EpCAM than cultured cells used for these exper-
iments and may evade capture. PSMA based CTC capture may
be able overcome this limitation in prostate cancer patients and
enable the capture of CTCs that have undergone EMT. PSMA,
also known as glutamate carboxypeptidase II, is a type II trans-
membrane metallopeptidase that is universally expressed in pro-
static tumors and may be conserved during EMT. Furthermore,
levels of expression correlate with disease severity, suggesting util-
ity as a prognostic marker (Bostwick et al., 1998; Sweat et al.,
1998). Although it is normally expressed as a cytoplasmic pro-
tein in benign prostatic cells, alternative splicing of PSMAmRNA
in prostatic carcinomas leads to its expression as a type II inte-
gral surface membrane protein, making it a suitable target for
anti-PSMA antibody based capture (Israeli et al., 1993). Although
this marker is not entirely specific to prostatic cells, expression
in this population is 100–1000 times greater than cells in other
tissue types such as cells of the small intestine, proximal renal
tubules, and salivary glands (Troyer et al., 1995; Sokoloff et al.,
2000). The J591 antibody is a deimmunizedmonoclonal antibody
that specifically recognizes an extracellular epitope of PSMA. This
antibody has been used successfully to capture CTCs from whole
blood using a geometrically-enhanced differential immunocap-
ture (GEDI) microfluidic device (Figure 2) (Gleghorn et al.,
2010). The PSMA-GEDI “chip” is designed to maximally increase
the frequency of CTC collisions with anti-PSMA immunocoated
posts in a size and flow-dependent manner. Size-based selection
is thought to increase capture efficiency and improve purity by
limiting opportunities for non-target blood cells to interact with
the immunocoated surfaces. The capture efficiency of the PSMA-
coated GEDI chip is quite high, 97 ± 3% for cells spiked in PBS
and 85 ± 5% for cells spiked in whole blood (Gleghorn et al.,
2010).
CURRENT AND FUTURE APPLICATIONS OF CTC
ENRICHMENT DEVICES
The FDA approved the CellSearch device for monitoring disease
status in patients with metastatic prostate cancer (Wang et al.,
2011). Studies using this device have demonstrated that prostate
cancer patients with at least 5 CTCs in 7.5ml of blood have an
inferior overall survival compared with patients with less than 5
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FIGURE 2 | Geometrically-enhanced differential immunocapture (GEDI) microfluidic device. (A) GEDI Chip (B) GEDI post-array (C) Illustration of laminar
flow through GEDI device (D) Captured CTCs stained for AR and tubulin.
CTCs in 7.5ml (Danila et al., 2007). The IMMC38 trial, which
provided the basis of FDA clearance of the CellSearch device
in prostate cancer, reported that a CTC count greater than 4
cells/7.5 ml is associated with unfavorable response to therapy in
metastatic castrate-resistant prostate cancer patients (Scher et al.,
2009). Several subsequent studies did not detect a threshold effect;
suggesting the use of CTC counts as a continuous variable with-
out a specific cutoff value (Danila et al., 2007). Nevertheless,
chemotherapy-naïve patients with CTC counts greater than 4
cells/7.5 ml have a 45% decrease in overall survival when com-
pared to those with fewer than 5 CTCs. The impact of CTC
counts is even greater in patients who had undergone one or
more chemotherapeutic regimens, where patients had a 60%
decrease in overall survival (Danila et al., 2007). CTC counts are
also useful in patients with hormone-sensitive PC. A CTC cut-
off of three or more cells, detected using the CellSearch device
was able to predict the magnitude and duration of response to
androgen deprivation therapy in these patients (Goodman et al.,
2011). Studies also compared CTC counts with traditional mark-
ers of disease progression and found that it is a more powerful
predictor of survival and therapeutic response than currently
used biomarkers such as PSA (de Bono et al., 2008; Scher et al.,
2009).
The number of prostate cancer CTCs has also been stud-
ied as a secondary endpoint in a number of clinical trials. Two
recent phase II trials examined the efficacy of abiraterone acetate,
a CYP17 inhibitor that impairs androgen synthesis, in patients
with castration resistant prostate cancer used CTCs as efficacy
markers. In one study, CTCs were isolated from patient blood
by use of the CellSearch Circulating Tumor Cell Test prior to
treatment and every 4 weeks during treatment. The authors
found significant declines in CTC counts of treated patients,
with 63% of patients having a greater than 50% decrease in
CTCs. This decline mirrored the PSA decline in a subset of
patients with ERG gene mutations (Reid et al., 2010). A second
study, which aimed at defining the efficacy of abiraterone com-
bined with prednisone in metastatic castrate-resistant prostate
cancer patients who failed first line chemotherapy used con-
version from unfavorable to favorable CTC counts as a sur-
rogate of clinical response. The authors reported that 34% of
treated patients who had pre-treatment CTC counts greater than
5 cells/7.5 ml had a decrease in CTC counts to less than 5
cells/7.5ml (Danila et al., 2010). Several recently reported and
ongoing phase III studies are validating this biomarker as a
potential surrogate marker of response and survival (Scher et al.,
2011).
Although still in its early stages, molecular and genetic analyses
of CTCs have also been used to correlate CTC characteristics with
treatment outcomes. For example, a study using FISH to detect
the fusion gene TMPRSS2-ERG demonstrated a significant asso-
ciation between expression of this marker and PSA response to
abiraterone. Furthermore, this study also demonstrated a high
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degree of concordance between the presence of the fusion gene
in CTCs and in primary prostatic tumors, further supporting the
utility of CTCs as a “liquid biopsy” (Attard et al., 2009). A sec-
ond study examining TMPRSS2-ERGmRNA in CTCs showed no
relationship to patient outcomes (Gopalan et al., 2009; Fine et al.,
2010).
Studies have also examined the predictive value of nuclear
and/or cytoplasmic localization of AR in CTCs. The AR plays
a key role in the development and progression of prostate can-
cer. In hormone-sensitive prostate cancer, systemic androgens
induce AR-mediated cellular proliferation, which is impaired by
androgen deprivation therapy by preventing ligand-dependent
nuclear AR translocation. AR signaling can continue to stimu-
late tumor growth in castrate patients via intra-tumoral androgen
synthesis or constitutive AR activation-independent of ligand
binding (Chen et al., 2004). Recent studies suggest that tax-
ane chemotherapy in prostate cancer can impede AR translo-
cation from the cytoplasm to the nucleus by disrupting micro-
tubules that normally function to transport AR to the nucleus
(Darshan et al., 2011). In a pilot study of patients receiving
taxane chemotherapy, examination of AR nuclear localization
and microtubule integrity in CTCs isolated using the CellSearch
Circulating Tumor Cell Test device correlated with response to
therapy (Darshan et al., 2011). In an unrelated study, PCR based
analysis of prostate cancer CTCs detected several AR mutations
some of which have been associated with therapeutic resistance
to anti-androgen therapy (Jiang et al., 2010). Recent studies
have also shown that AR splice variants may evolve with ther-
apy and be a mechanism of treatment resistance (Sun et al.,
2010; Guo and Qiu, 2011; Mostaghel et al., 2011). Studies are
in progress to determine if these abnormalities in AR that
could affect treatment decisions can be detected by examining
CTCs.
CONCLUSION
The science of CTC capture and analysis is evolving and will
certainly change as newer technologies are incorporated and
validated. The only FDA-cleared device, CellSearch system, has
been shown to be an important prognostic tool, providing
valuable insights into treatment response and overall survival.
Experiments with alternative enrichment methods highlight the
poor sensitivity of the CellSearch technique, with multiple stud-
ies demonstrating significantly higher capture rates from patient
with metastatic castrate-resistant prostate cancer. However, their
clinical utility remains to be confirmed. Further studies are
needed to improve and validate alternative enrichment in iden-
tification techniques.
The effect that CTC analysis will have on patient care remains
to be determined. As discussed, genetic analysis of CTCs has
enabled the detection of abnormalities that influence tumor sensi-
tivity to a variety of prostate cancer therapies. Molecular analysis
has helped elucidate the mechanism of taxane anti-tumor effect
in prostate cancer, and provides a basis for an assay to assess the
likely efficacy of this chemotherapeutic class. Future studies will
be aimed at assessing additional markers of treatment sensitiv-
ity and resistance, and attempting to ascertain additional drug
targets. Additional studies correlating the molecular features of
CTCs with those of tissue specimens obtained from primary and
metastatic sites are needed. The ultimate goal is to develop tech-
nology that will enable periodic monitoring of tumor biology in
a way that will enable clinicians to effectively tailor therapy to
the individual patient on an ongoing basis in order to maximize
patient outcomes.
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